Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | CFD | P00746 | 2/20 | 0.37 |
| ▸ | F11 | P03951 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365641 | 0.72 | HTR2A (0.43) | HTR2AHTR2CMAOA | |
| SCHEMBL629337 | 0.72 | HTR2A (0.52) | HTR2AHTR2CPTPN1MAOAMAOB | |
| SCHEMBL2365632 | 0.71 | ADRA2A (0.37) | — | |
| SCHEMBL2365770 | 0.70 | TNFRSF1A (0.37) | HTR2AHTR2C | |
| SCHEMBL2477900 | 0.70 | HTR2A (0.58) | HTR2AHTR2CSLC6A4 | |
| SCHEMBL6631310 | 0.70 | FGFR4 (0.35) | HTR2AHTR2C | |
| SCHEMBL6653629 | 0.69 | ADRA2A (0.35) | HTR2AHTR2CPTPN1 | |
| SCHEMBL6650634 | 0.69 | ALDH1A1 (0.39) | HTR2AHTR2C | |
| SCHEMBL1095655 | 0.68 | HTR2A (0.56) | HTR2AHTR2C | |
| SCHEMBL1095724 | 0.68 | HTR2C (1.00) | HTR2AHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363394-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |